ClinicalTrials.gg
TerminatedNCT05953688OPTYK-1Updated Aug 28, 2024

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

A Phase 2 interventional study of ESK-001 in Uveitis Posterior Non-Infectious, Uveitis, Intermediate and Noninfectious Panuveitis, sponsored by Alumis Inc. Terminated at 17 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by Alumis Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated based on interim efficacy data that did not meet the Sponsor's criteria.

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Uveitis, Intermediate with a site in United States — 2 open to participants now, 5 under way, 1 of them phase 3. Uveitis, Intermediate · United States.

Enrollment
17th of 39
36 · median 30
Started
2023
the only one that year
Phase 2
8 of 44
none open now
Registered
42nd of 44
by date

Among the 44 studies in Uveitis, Intermediate with a site in United States, this one is the 17th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2023, is one of 8 in phase 2, and was the 42nd registered.

Uveitis, Intermediate

56 studies on the registry are indexed under Uveitis, Intermediate; 2 are open to participants now.

Browse Uveitis, Intermediate studies →

Open to participants now

2 of the 44 studies in Uveitis, Intermediate with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Uveitis, Intermediate study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Uveitis, Intermediate with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.

Read the detailed description

This study will consist of a 2-week screening period (+7 days), 24-week treatment period, followed by a 24-week extension period, and a 4-week follow up period for a total of up to 55 weeks. Each participant will be randomized to receive one of two doses of ESK-001 daily for 24 weeks. Participants that do not meet the treatment failure criteria at Week 24 will continue into the extension period.

03

Conditions studied

  • Uveitis Posterior Non-Infectious
  • Uveitis, Intermediate
  • Noninfectious Panuveitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able and willing to provide consent
  • Male and females, age 18 to 70 years
  • Diagnosis of active noninfectious intermediate, posterior or panuveitis
  • Must have active uveitis at Screening in at least one eye as defined by:

    1. Active inflammatory chorioretinal and/or inflammatory retinal vascular lesion or lesions, or
    2. ≥ 2+ VH in accordance with the NEI/SUN criteria
  • Males and females must use highly effective methods of for the entirety of the study

Key Exclusion Criteria:

  • Diagnosis of infectious uveitis
  • Has elevated intraocular pressures or severe glaucoma
  • Positive for , or C or active or inadequately latent tuberculosis at screening
  • Positive for syphilis at screening
  • Patients with >450 msec (both males and females) at screening
  • Known active or history of malignancy within the past 5 years
  • History of chronic drug or alcohol abuse
  • No planned ocular or any other surgery during the course of the study

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    ESK-001 Dose Level 1

    ESK-001 administered as an oral tablet

    Drug: ESK-001

  • Experimental
    ESK-001 Dose Level 2

    ESK-001 administered as an oral tablet

    Drug: ESK-001

Interventions

06

What researchers measure

Primary outcomes

  1. To compare the efficacy between 2 ESK-001 treatment groups for the treatment of active NIU as measured by the proportion of patients failing treatment by Week 24

    The proportion of patients failing treatment for active NIU by Week 24 between 2 ESK-001 treatment groups. Treatment failure is defined as a patient meeting at least 1 of the treatment failure criteria in at least 1 eye at Week 24.

    Time frame: 24 Weeks

Secondary outcomes

  1. To compare the efficacy between 2 ESK-001 treatment groups for the treatment of active NIU as measured by the time to treatment failure on or after Week 24

    Time to treatment failure on or after Week 24 between 2 ESK-001 treatment groups. Time to treatment failure is defined as time to the visit of the first treatment failure as defined per protocol. Median time to treatment failure in each treatment group will be reported and compared.

    Time frame: 24 Weeks

  2. To assess the safety and tolerability of ESK-001 in patients with active NIU by comparing the incidence and proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

    Clinical and laboratory assessments including blood tests, ECGs, hematological measures and physical examinations throughout the study. The number and proportion of TEAEs, SAEs, AEs leading to study discontinuation, and AEs of greater than grade 3 severity will recorded per treatment group and across all groups.

    Time frame: Through study completion, up to 52 weeks

  3. To characterize the pharmacokinetics (PK) of ESK-001 (Cmax)

    Plasma concentrations and PK parameters including steady-state maximum observed concentration (Cmax) for ESK-001 at Day 1, Week 24, and Week 48.

    Time frame: Through study completion, up to 48 weeks

  4. To characterize the pharmacokinetics (PK) of ESK-001 (Ctrough)

    Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001 at Week 24, and Week 48.

    Time frame: Through study completion, up to 48 weeks

07

Study locations

17 sites
  • Investigator Site#1065
    Beverly Hills, California 90211, United States
  • Investigator Site #1073
    Los Angeles, California 90033, United States
  • Investigator Site #1072
    Los Angeles, California 90095, United States
  • Investigator Site #1080
    Palo Alto, California 94303, United States
  • Investigator Site #1079
    Sacramento, California 95825, United States
  • Investigator Site#1068
    Lakewood, Colorado 80228, United States
  • Investigator Site #1086
    Oak Park, Illinois 60304, United States
  • Investigator Site #1085
    Hagerstown, Maryland 21740, United States
  • Investigator Site #1069
    Waltham, Massachusetts 02451, United States
  • Investigator Site #1076
    Palisades Park, New Jersey 07650, United States
  • Investigator Site #1083
    Durham, North Carolina 27705, United States
  • Investigator Site #1064
    Erie, Pennsylvania 16507, United States
  • Investigator Site#1066
    Nashville, Tennessee 37203, United States
  • Investigator Site #1084
    Nashville, Tennessee 37232, United States
  • Investigator Site#1075
    Bellaire, Texas 77401, United States
  • Investigator Site #1074
    Katy, Texas 77494, United States
  • Investigator Site #1078
    Plano, Texas 75075, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Aug 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 20, 2023
StartActual
Jun 14, 2023
Primary completionActual
Aug 13, 2024
CompletionActual
Aug 13, 2024
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05953688
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Jun 14, 2023
Primary completion
Aug 13, 2024
Completion
Aug 13, 2024
Last update
Aug 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion